Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: Administrative claims analysis

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1711-1719

  Halpern, Rachel ^a   Mody, Reema R ^b   Fuldeore, Mahesh J ^c   Patel, Pankaj A ^c   Mikuls, Ted R ^d  

^a MN002 0258 ^*  (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Allopurinol therapeutic use; Gout drug therapy; Healthcare costs; Patient compliance; Retrospective studies; Uric acid blood

Indexed keywords

ALLOPURINOL; COLCHICINE; PROBENECID; SULFINPYRAZONE; URATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GOUT; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; GOUT; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PATIENT COMPLIANCE; URIC ACID; URICOSURIC AGENTS; YOUNG ADULT;

EID: 67650469666     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903017966     Document Type: Article

References (30)

1. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-994. Am J Kidney Dis 2002; 40:37-42
2. Porter RS, Kaplan JL, Homeier BP, et al., eds. The Merck Manual, 2008. Whitehouse Station, NJ: Merck Research Laboratories. Available as part of The Merck Manuals Online Medical Library, at: http://www.merck.com/mmpe/index.html [Last accessed 25 February 2008].
3. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999;59:1799-806, 1810
4. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005;11(15 Suppl): S443-50
5. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81
6. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32
7. Cannella AC, Mikuls TR. Understanding treatments for gout. Am J Manag Care 2005;11(15 Suppl):S451-8
8. Lacy CF, Armstrong LL, Goldman MP, et al. Drug Information Handbook, 14th edn. Hudson, OH: Lexi-Comp, 2006
9. McEvoy GK, ed. AHFS Drug Information® (2006). Available via STAT! Ref Online Electronic Medical Library, at: http:// online.statref.com/document. aspx?fxid=1&docid=1230
10. Kim KY, Schumacher R, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617
11. Wu EQ, Patel PA, Yu AP, et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008;14:164-75
12. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-9
13. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007; 10:231-7
14. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care 2005;11:S459-64
15. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57
16. Wortmann RL. Gout and other disorders of purine metabolism. In: Harrison TR, Fauci AS, eds. Harrison's Principles of Internal Medicine, 14th edn. New York, NY: McGraw-Hill, 1998
17. Emerson BT. The management of gout. N Engl J Med 1996; 334:445-51
18. Li-Yu J, Clayburne G, Steck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28: 577-80
19. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attack of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321-5
20. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55
21. Halpern R, Fuldeore MJ, Mody, RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009;15:3-7
22. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administration data. Med Care 1998;36:8-27
23. Agency for Healthcare Research and Quality. Comorbidity Software, Version 3.0. Available at: http://www.hcup-us.ahrq. gov/toolssoftware/comorbidity/ comorbidity.jsp. [Last accessed 6 August 2008].
24. StataCorp. 2003. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation.
25. Vawter RL, Antonelli MAS. Rational treatment of gout. Postgrad Med 1992;91:115-16, 118, 127
26. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72
27. de Klerk E, van der Heijde D, Landewé R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54
28. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9
29. Mikuls TR, Curtis JR, Allison JJ, et al. Medication errors with the use of allopurinol and colchicines: a retrospective study of a national, anonymous internet-accessible error reporting system. J Rheumatol 2006;33:562-6
30. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results for the UK General Practice Research Database (GPRD). Rheumatology 2005; 44:1038-42